Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1872631 | 1.00 | BCL2 (0.56) | BCL2BCL2L1 | |
| SCHEMBL1871302 | 0.96 | BCL2 (0.52) | BCL2BCL2L1 | |
| SCHEMBL1870327 | 0.93 | BCL2 (0.50) | BCL2BCL2L1 | |
| SCHEMBL1862589 | 0.93 | BCL2 (0.48) | BCL2BCL2L1 | |
| SCHEMBL2725177 | 0.92 | BCL2 (0.54) | BCL2BCL2L1 | |
| SCHEMBL2727377 | 0.92 | BCL2 (0.54) | BCL2BCL2L1 | |
| SCHEMBL2724284 | 0.91 | BCL2 (0.51) | BCL2BCL2L1 | |
| SCHEMBL1868681 | 0.91 | BCL2 (0.49) | BCL2BCL2L1 | |
| SCHEMBL30622012 | 0.90 | BCL2 (0.52) | BCL2BCL2L1 | |
| SCHEMBL1871281 | 0.89 | BCL2 (0.45) | BCL2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023161940-A1 | APOPTOSIS RELATED PROTEIN IN THE TGF-BETA SIGNALING PATHWAY (ARTS) MIMETIC COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF IN INDUCTION OF APOPTOSIS | CARMEL-HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) | 2023-08-31 | — | — | WO | claimed |
| WO-2023161940-A1 | APOPTOSIS RELATED PROTEIN IN THE TGF-BETA SIGNALING PATHWAY (ARTS) MIMETIC COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF IN INDUCTION OF APOPTOSIS | CARMEL-HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) | 2023-08-31 | — | — | WO | disclosed |
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-3978494-A1 | METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | BCL2 1/4885BCL2L1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.